Light-modulating cosmetic composition and use thereof

Abstract

Provided herein are cosmetic compositions capable of modulating light emitted from a non-uniform light emitting source to balance light received on a target tissue, such as irradiance, and consumer products containing light modulating cosmetic compositions. Methods of making and using the light-modulating cosmetic compositions and consumer products are also provided.

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to U.S. Provisional Application No. 63 / 394,751, filed on August 3, 2022, the contents of which are hereby incorporated by reference in their entirety. Technical Field

[0003] Provided herein are cosmetic compositions and consumer products containing light-modulating cosmetic compositions that can modulate light emitted from a non-uniform light emitting source to balance the light, such as irradiance, received on a target tissue. Also provided are methods of making and using the light-modulating cosmetic compositions and consumer products. Background Art

[0004] Unlike the sun, which emits a balanced visible spectrum known as white light, digital screens from computers and smartphones and other artificial light sources (e.g., fluorescent lamps, LEDs) emit unbalanced (non-uniform) light with a strong peak in the blue light range. White light has beneficial effects on the skin and the health of the subject, while artificial light is particularly associated with biological skin perturbations, among other things. Despite this, adults spend a lot of time in front of non-uniform light sources (e.g., computer screens), which can negatively affect skin health and overall well-being.

[0005] Typical strategies for protecting against the negative effects of non-uniform light sources attenuate the emitted blue light. However, these strategies do not modulate the light emitted from the non-uniform light source to generate a balanced irradiance profile that can produce beneficial results. Therefore, new strategies are needed to convert the potentially harmful light emitted from the non-uniform light source into a more balanced light, such as white light, that can deliver beneficial effects. Compositions and methods that address these and other needs in the art are provided herein. Summary of the invention

[0006] In one aspect, a light-modulating cosmetic composition is provided that includes one or more photoluminescent compounds, wherein the composition modulates the irradiance of a non-uniform light-emitting source on a target tissue.

[0007] In one aspect, a consumer product is provided, comprising the light-modulating cosmetic composition described herein. In some embodiments, the consumer product is a cream, lotion, gel, foam, paste, salve, balm, varnish, or ointment.

[0008] In one aspect, a method of modulating irradiance from a non-uniform light emitting source on a target tissue is provided, comprising topically applying a light-modulating cosmetic composition or consumer product described herein to the target tissue.

[0009] In one aspect, provided are methods of reducing or preventing photodamage to a target tissue from light emitted from a non-uniform light emitting source comprising topically applying a light-modulating cosmetic composition or consumer product described herein to the target tissue.

[0010] In one aspect, provided are methods of reducing or preventing aging of a target tissue from light emitted from a non-uniform light emitting source, comprising topically applying a light-modulating cosmetic composition or consumer product described herein to the target tissue.

[0011] In one aspect, provided are methods of reducing or preventing oxidative stress in a target tissue from light emitted from a non-uniform luminescent source, comprising topically applying a light-modulating cosmetic composition or consumer product described herein to the target tissue.

[0012] In one aspect, methods of modulating photoactivation of chromophores in a target tissue by light emitted from a non-uniform light emitting source are provided, comprising topically applying a light-modulating cosmetic composition or consumer product described herein to the target tissue.

[0013] In one aspect, provided are methods of improving the appearance of a target tissue exposed to light emitted from a non-uniform light emitting source comprising topically applying a light-modulating cosmetic composition or consumer product described herein to the target tissue.

[0014] In one aspect, provided are methods of improving the well-being of a subject exposed to light emitted from a non-uniform light emitting source comprising topically applying a light-modulating cosmetic composition or consumer product described herein to a target tissue.

[0015] In one aspect, a method of preparing a consumer product is provided, comprising: (a) adding a light modulating cosmetic composition as described herein to a cosmetic base to form a mixture; and (b) stirring the mixture to achieve homogeneity. In some embodiments, the method comprises emulsifying the mixture. In some embodiments, the method comprises cooling the mixture. In some embodiments, the method comprises adjusting the pH of the mixture.

[0016] In one aspect, a kit is provided comprising a light-modulating cosmetic composition as described herein and instructions for use.

[0017] Each of the aspects and embodiments described herein can be used together unless explicitly or clearly excluded from the context of the embodiment or aspect. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 Coupled absorption and emission spectra of exemplary test mixtures are shown (see Section V, Table El).Emission spectra were obtained by illuminating the exemplary test mixtures with monochromatic light at 455 nm.

[0019] Figure 2 Shown is the experimental design for evaluating the photoconversion effect of exemplary test mixtures (see Section V, Table El) when illuminated by a digital screen.

[0020] Figure 3 An exemplary computer screen emission spectrum (30 cm) is shown.

[0021] Figure 4A-4B The results are shown when an exemplary computer screen ( Figure 4A ) or an exemplary smartphone screen ( Figure 4B ) is the visible light modulation determined by measuring the irradiance of an exemplary test mixture (see Section V, Table E1) when illuminated at a distance of 30 cm. Figure 4C-4E The results show that the exemplary test mixture and placebo at 450 nm ( Figure 4C )、540 nm ( Figure 4D ) and 600 nm ( Figure 4E ) is the irradiance measured once an hour for 8 hours.

[0022] Figure 5 Shown are the mean percentages ± standard deviations of positive surfaces stained for 8-OHdG in skin explants that were untreated and not exposed to blue light, untreated and exposed to blue light conditions, treated with placebo and exposed to blue light, and treated with an exemplary test mixture and exposed to blue light. Results were normalized to untreated, unexposed reference conditions. Statistical significance was assessed using the Mann-Whitney test (****p<0.0001).

[0023] Figure 6 Shown are the mean percentages ± standard deviations of cytochrome c oxidase (CCO) activity in skin explants that were untreated and not exposed to blue light, untreated and exposed to blue light, treated with a placebo and exposed to blue light, and treated with an exemplary test mixture and exposed to blue light. Results were normalized to untreated, unexposed reference conditions. Unpaired T-tests were used to assess statistical significance (***p<0.0001, **p<0.001, #p<0.1).

[0024] Fig. 7A Shown is opsin 1SW expression using immunostaining in healthy human explants treated with an exemplary test mixture (see Section V, Table E1), placebo or untreated after 8 days of daily exposure to blue light. Figure 7B Shown is opsin 2 expression using immunostaining in healthy human explants treated with an exemplary test mixture, placebo, or untreated after 8 days of daily exposure to blue light. Figure 7C The mean percentage ± standard deviation of surface staining for opsin 1SW and opsin 2 between treatment conditions is shown. These values ​​were normalized to 100% of the untreated, unexposed condition. Significance levels were set at *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001 using the Mann-Whitney test.

[0025] Fig. 8A The emission at 512 nm of an exemplary photoluminescent mixture (see Example 1) in electroluminescent water and non-electroluminescent water immediately after blue light exposure (482 nm) is shown. Figures 8B-8C It is shown that in ultrapure water ( Figure 8B ) or in ultrapure electromagnetically irradiated water ( Figure 8C ). A droplet containing 0.00015% of the photoluminescent mixture (white) was placed in a 3D image. After evaporation of the droplet, water structuring was observed using an epifluorescence microscope at a magnification of X40 after exposure to 482 nm blue light. Scale bar = 20 µm.

[0026] Fig. 9A Grayscale brightness evaluated on several areas of the face (white outlines) before and after exposure to blue light (405 nm) is shown. The images illustrate the emission of light at 560 nm. Fig. 9B The mean percentage ± standard deviation of grayscale brightness at 560 nm over a defined area immediately after or 10 minutes after application of an exemplary clinical test mixture (see Example 4, Table E4; dark bars) or placebo (light bars) under exposure to blue light is shown. The results are normalized to 100% of the area exposed to white light (before). Statistical significance was assessed using a two-way Anova test (*p<0.05; **p<0.01).

[0027] Figures 10A-10F is a bar graph comparing various skin conditions in healthy volunteers who applied an exemplary clinical test mixture or a clinical placebo (C. Test mixture or C. Placebo; see Example 4, Table E4) twice daily (morning and evening) and spent at least 6 hours per day in front of a screen emitting blue light. Fig. 10A Displays the color of dark circles as ITA°. Fig. 10B Shows antioxidant potential. Fig. 10C Shows skin radiance. Fig. 10D Skin redness is shown. Fig. 10E The volume of the wrinkles is shown. Fig.10FSkin roughness is shown. All evaluations were performed on the 28th day of application, and the values ​​were normalized to 100% of the values ​​on day 0. Mann-Whitney test was used, with significance thresholds of **p≤0.01, ***p≤0.001, ****p≤0.0001, *****p≤0.00001.

[0028] Figures 11A-11C Measures of well-being were compared in healthy volunteers who applied an exemplary clinical test mixture or a clinical placebo (C. Test mixture or C. Placebo; see Example 4, Table E4) twice daily (morning and evening) and spent at least 6 hours per day in front of a screen emitting blue light. On day 28, stress was assessed by measuring the volunteers' energy field ( Fig.11A ), the energy of each chakra ( Fig. 11B ) and the overall energy of the chakra ( Fig. 11C ). Values ​​were normalized to 100% of the value on day 0. Mann-Whitney test was used with significance thresholds of ****p≤0.0001, ****p≤0.00001. DETAILED DESCRIPTION

[0029] Sunlight is a source of energy that enables a wide range of chemical reactions in the biological world, and its absorption at different wavelengths produces a wide range of molecules that are essential for biological functions in plants and animals. Many organisms, from bacteria to insects, sharks and birds, can light up in the dark and emit light. These biofluorescent animals absorb short-wavelength electromagnetic radiation and re-emit it at longer wavelengths, which results in bright fluorescent light emission. This phenomenon that facilitates communication is based on several types of proteins, pigments, metabolites and chemical reactions.

[0030] Humans do not perform photosynthesis, yet human skin is the organ that interacts most with ambient light, some of which can penetrate some or all layers of the skin, depending on its wavelength. Visible light is a medium used to improve the appearance of the skin by rejuvenation, anti-aging, anti-oily or acne-prone skin, and by effects on pigmentation or skin whitening, dandruff and other skin diseases associated with Malassezia, etc. The use of light as therapy is based on photobiomodulation, which modulates chromophores in the skin and activates their biological activity. Retinal photoreceptors, called opsins, have been shown to exist in the skin as photoreceptors. Opsins are a large group of photosensitive G protein-coupled receptors (GPCRs), whose activation triggers excitation wavelength-dependent signaling cascades. Therefore, the expression of these skin photoreceptors reflects the wavelength to which the skin is exposed.

[0031] Electromagnetic radiation from the sun is the main source of visible light exposed to our skin, but not the only source. Artificial light sources, such as light emitting diodes (LEDs), flashlights, computers, televisions, and mobile phones (e.g., smart phones) are also sources of visible light. Unlike the sun, which emits a balanced visible light spectrum called white light, artificial light sources, such as but not limited to digital screens from computers and smart phones, emit unbalanced light with strong peaks in the blue light range. These and other unbalanced light sources are generally referred to as non-uniform light sources in this article. White light has a beneficial effect on the skin and well-being of the subject (human subject), while artificial light is associated with biological skin disturbances. Examples of such disturbances include, but are not limited to, skin wrinkles, dark circles, oxidative stress, light damage, light aging, and rough, red, dull, and inflamed skin. Exposure to non-uniform light sources can also affect, for example, the emotional stress level, energy level, and circadian rhythm of the subject, which may negatively affect their well-being. Despite this, adults spend about 11 hours a day in front of the screen. In addition, many use other non-uniform light emitting devices (second screens) at the same time.

[0032] Unbalanced visible light can be modulated by fluorescence mechanism. Modulation strategies usually focus on absorbing harmful light to reduce the intensity of harmful light received by the subject. However, these strategies fail to convert harmful light into more balanced beneficial light by re-emitting energy of higher wavelengths. Compositions provided herein (e.g., light modulating cosmetic compositions and consumer products containing such compositions) use light emitted from a non-uniform luminous source as an energy source, and convert non-uniform light into a more balanced wavelength mix, such as white light. Compositions provided herein are beneficial in their following capabilities: protecting the skin from the influence of harmful wavelengths and providing skin health benefits at the same time. Another advantage of compositions provided herein is their commercial cosmetic availability. For example, compositions provided herein can be used as cosmetic consumer products without undergoing therapeutic treatment.

[0033] Thus, light modulating cosmetic compositions and consumer products containing light modulating cosmetic compositions are provided herein. Methods and uses of such light modulating cosmetic compositions and consumer products are also provided. In some aspects, methods for preparing consumer products containing light modulating cosmetic compositions and kits containing light modulating cosmetic compositions are provided.

[0034] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.

[0035] The present disclosure is not limited to the exemplary methods and materials disclosed herein, and any methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the present disclosure.

[0036] The titles provided herein are not limitations of the various embodiments or aspects of the present disclosure, and various aspects or embodiments of the present disclosure can be obtained by reference to the specification as a whole. The section titles used herein are only for organizational purposes and should not be interpreted as limiting the subject matter described. Any term defined is more fully defined by reference to the specification as a whole.

[0037] All publications referred to in this application, including patent documents, scientific articles and databases, are incorporated by reference in their entirety for all purposes to the same extent as if each individual publication were individually incorporated by reference. Nothing herein should be construed as admitting that such publications constitute prior art. If the definitions shown herein are contrary to or otherwise inconsistent with the definitions shown in the patents, applications, published applications and other publications incorporated herein by reference, then the definitions shown herein take precedence over the definitions incorporated herein by reference.

[0038] All features disclosed in this specification may be combined in any combination. Each feature disclosed in this specification may be replaced by an alternative feature serving the same, equivalent or similar purpose. Therefore, unless otherwise expressly stated, each feature disclosed is merely an example of a series of equivalent or similar features.

[0039] definition

[0040] Definitions of terms may appear throughout the specification. It will be understood that the present disclosure is not limited to the particular embodiments described, and as such may, of course, vary. It will also be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.

[0041] It must be noted that, as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. For example, "a" or "an" includes "at least one" and "one or more."

[0042] As used herein, the terms "comprising," "comprises," and "comprised of" are synonymous with "including," "includes," "containing," "contains," and grammatical variations thereof, are inclusive or open-ended, and do not exclude additional, unrecited members, elements, or method steps. The terms "comprising," "comprises," and "comprised of," "including," or "containing," "contains," and grammatical variations thereof also include the term "consisting of."

[0043] The term "skin" and its grammatical variants refer to any part of human skin, including facial (including lips and eyelids) skin, eye fundus skin, neck, scalp and hand skin. In some embodiments, the target tissue described herein is the skin at the facial level (including eye contour and lip contour) and the neck level.

[0044] "Prevent," "preventing," "prevention," "inhibit," "inhibiting," "inhibiting," "inhibition," and grammatical variations thereof mean delaying or preventing the appearance of a sign, effect, or condition. "Reducing," "reduction," and grammatical variations thereof, as referred to in connection with the methods and uses described herein, refer to lowering, attenuating, decaying, correcting, or slowing the development of the sign, effect, or condition. In some embodiments, reduction of any sign, effect, or condition described herein (e.g., skin condition, well-being condition) comprises a reduction of about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, including all values ​​falling between these percentages, in the expression of the sign, effect, or condition prior to use of the compositions described herein. In some embodiments, the reduction of any sign, effect or condition described herein (e.g., skin condition, well-being condition) includes a reduction of about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% in the expression of the sign, effect or condition relative to a subject with the sign, effect or condition and not applying the composition described herein, including all values ​​falling between these percentages. In some embodiments, the sign, effect or condition is an adverse effect described herein. In some embodiments, the beneficial effect as described herein is to prevent or inhibit an adverse effect described herein.

[0045] When providing a numerical range, it should be understood that, unless the context clearly indicates otherwise, each intermediate value between the upper and lower limits of the range is also specifically disclosed, to one tenth of the lower limit unit. Each smaller range between any specified value or intermediate value in the specified range and any other specified value or intermediate value in the specified range is included in the present disclosure. The upper and lower limits of these smaller ranges can be independently included in the range or excluded from the range, and each range in which any one limit, both limits are not included, or both limits are included in the smaller range is also included in the present disclosure, and is affected by any specific excluded limits in the specified range. Where the range includes one or both of the limits, the range excluding any one or both of these included limits is also included in the present disclosure.

[0046] In this article, values ​​and ranges can be presented with the term "about" in front of the numerical value. The term "about" is used herein to provide textual support for the exact number that precedes it and the number that is close to or approximately the number that the term precedes. In determining whether a number is close to or approximates a specifically described number, the number that is close to or approximate without narration can be a number that provides a basic equivalent to the number of the specific narration in the context of its presentation. For example, with respect to numerical values, the term "about" refers to a range of -10% to +10% of the numerical value, unless the term is specifically defined otherwise in the context. Unless the context otherwise provides, all values ​​and ranges may implicitly include the term "about".

[0047] As used herein, the term "consumer" means a user of a cosmetic composition or consumer product and observers near or around the user.

[0048] Abbreviations used herein have their conventional meanings in the fields of chemistry, physics and biology.

[0049] I. Light-modulating cosmetic compositions and consumer products thereof

[0050] Provided herein is a cosmetic composition having a light modulating activity, which is generally referred to herein as a light modulating cosmetic composition. The light modulating cosmetic composition described herein modulates light from a non-uniform luminescent source to convert the non-uniform light emitted from the source into light with a beneficial effect, and the non-uniform luminescent source has the following emission profile: high intensity peaks are displayed in one or more wavelengths or wavelength bands known to have adverse effects on tissues (e.g., human tissues such as skin, hair, and nails) and / or the well-being of the subject. In some embodiments, the adverse effects are the following or include the following: light damage, light aging, aging, oxidative stress, redness, wrinkles, fine lines, dark circles, emotional stress, and / or low chakra energy. In some embodiments, the adverse effects are the following or include the following: light damage, light aging, aging, oxidative stress, redness, wrinkles, fine lines, dark circles, or roughness of tissues exposed to non-uniform luminescent sources. In some embodiments, the adverse effects are the following or include the following: emotional stress or low chakra energy. Thus, in one aspect, a light modulating cosmetic composition is provided that contains one or more photoluminescent compounds, e.g., as described in Section IA below, that modulates the irradiance of a non-uniform light emitting source on a target tissue. The irradiance may be referred to as spectral irradiance. The target tissue is the tissue exposed to the non-uniform light source. In some embodiments, the subject is a human. In some embodiments, the target tissue is human tissue. In some embodiments, the target tissue is skin, hair, and / or nails. In some embodiments, the target tissue is skin. In some embodiments, the target tissue is facial skin. In some embodiments, the target tissue is the skin under the eyes. In some embodiments, the target tissue is hair. In some embodiments, the target tissue is nails.

[0051] In some embodiments, the light modulating cosmetic composition modulates the intensity of light in one or more of the ultraviolet spectrum, visible spectrum, or infrared spectrum emitted by a non-uniform light emitting source. In some embodiments, the modulation includes independently increasing, decreasing, or maintaining the intensity of the light. For example, in some embodiments, the light modulating cosmetic composition reduces the high intensity emission wavelength peak, increases the emission wavelength with an intensity lower than the peak emission wavelength, and maintains the intensity of the wavelength with an emission peak between the high intensity emission wavelength and the low intensity emission wavelength. Therefore, in some embodiments, the light modulating cosmetic composition independently modulates the intensity of different wavelengths from a non-uniform light emitting source to produce an emission profile with balanced light. In some embodiments, the balanced light includes a mixture of wavelengths with equal or approximately equal intensity. In some embodiments, the balanced light includes a mixture of wavelengths in which the emission profile does not have a strong peak. For example, the emission peak intensity differs by less than 20%, 15%, 10%, 5%, or 1%. In some embodiments, the modulation of the intensity is determined by measuring the irradiance (spectral irradiance). In some embodiments, the light modulating cosmetic composition can modulate the emission profile of a non-uniform light emitting source to produce white light. In some embodiments, the light-modulating cosmetic composition modulates the irradiance of a non-uniform light emitting source to produce white light. In this manner, for example, the light-modulating cosmetic composition converts non-uniform light from a non-uniform light emitting source including peak emission in a wavelength or wavelength band with known adverse effects into light having an emission profile with a beneficial effect. In some embodiments, the emission profile is or includes the visible spectrum.

[0052] In some embodiments, the beneficial effects are or include the following: reducing or preventing photodamage, photoaging, aging, oxidative stress, redness, wrinkles, fine lines, dark circles, and roughness of the target tissue. In some embodiments, the beneficial effects are or include the following: maintaining or improving the gloss, brightness, or smoothness of the target tissue. In some embodiments, the target tissue is a tissue exposed to a non-uniform light source. The target tissue can be any tissue described herein. In some embodiments, the beneficial effects are or include the following: improving or maintaining the well-being of the subject (e.g., a human subject). In some embodiments, well-being is or includes the following: reducing emotional stress and / or increasing chakra energy. The beneficial effects can be determined by comparing measurements made before and after use of a light-modulating cosmetic composition or a consumer product containing a light-modulating cosmetic composition (e.g., a consumer product described in Section IB). For example, the comparison can be made after 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or one year or more after use (e.g., continuous, intermittent or cyclic use). The beneficial effect can also be determined by comparison with subjects exposed to the same conditions but without the use of the light-modulating cosmetic composition or consumer product described herein. Non-limiting methods for evaluating the beneficial effect are described in Sections II and V below.

[0053] It is expected that the light modulating cosmetic composition described herein can be used to modulate the light intensity and irradiance of light emitted from a non-uniform light emitting source. As described above, a non-uniform light emitting source includes a light source having the following emission profile: having a high intensity peak in one or more wavelengths or wavelength bands known to have adverse effects on tissues (e.g., human tissues such as skin, hair, and nails) and / or the well-being of the subject. This type of emission profile is alternatively referred to as unbalanced herein. By unbalanced, it is meant light that does not contain a mixture of wavelengths of equal or approximately equal intensity, and it includes high intensity peaks in one or more wavelengths or bands known to have adverse effects on tissues (e.g., human tissues such as skin, hair, and nails) and / or the well-being of the subject. It should be understood that a non-uniform light emitting source can be a light source that emits a single wavelength or a narrow band of wavelengths (e.g., ±20 nm, ±10 nm, ±5 nm). In some embodiments, a single wavelength or a narrow band of wavelengths is known to have adverse effects on tissues (e.g., human tissues such as skin, hair, and nails) and / or the well-being of the subject.

[0054] In some embodiments, the non-uniform light source is an artificial light source. Examples of artificial light sources as non-uniform light sources include, but are not limited to: computers such as desktop computers, notebook computers, and tablet computers; mobile phones (cellular phones) such as smart phones; televisions; VR / AR devices; fluorescent lamps; and LEDs, and components thereof that emit non-uniform light, such as screens. In some embodiments, the non-uniform light source is a computer, such as a desktop computer, a notebook computer, and a tablet computer. In some embodiments, the non-uniform light source is a tablet computer. In some embodiments, the non-uniform light source is a mobile phone. In some embodiments, the non-uniform light source is a mobile phone as a smart phone. In some embodiments, the non-uniform light source is a smart phone. In some embodiments, the non-uniform light source is a television. In some embodiments, the component is a screen, such as a computer screen, a tablet computer screen, a television screen, a mobile phone screen. In some embodiments, the non-uniform light source is a light source that emits at least one non-uniform emission wavelength in the blue light spectrum. For example, the non-uniform light source is a light source with peak emission in the blue light spectrum. In some embodiments, the non-uniform light source comprises peak emission at a wavelength in the blue light spectrum.

[0055] A. Light-modulating cosmetic composition

[0056] Light-modulating cosmetic compositions having features described herein include photoluminescent compounds having the ability to modulate, for example, light intensity and irradiance from a non-uniform light emitting source on a target tissue. In some embodiments, the photoluminescent compound modulates the intensity of light in one or more of the ultraviolet spectrum, visible spectrum, or infrared spectrum emitted by the non-uniform light emitting source. In some embodiments, modulation includes independently increasing, decreasing, or maintaining the intensity of the light. In some embodiments, modulation includes balancing the intensity of light from the non-uniform light emitting source to produce a mixture of wavelengths with equal or approximately equal intensity. In some embodiments, the mixture of wavelengths with equal or approximately equal intensity is white light. In some embodiments, the photoluminescent compound modulates the irradiance of the non-uniform light emitting source on the target tissue to, for example, produce white light. In some embodiments, the light-modulating cosmetic composition includes one or more photoluminescent compounds, wherein the compounds modulate light of the same or different wavelengths. In some embodiments, each of the one or more compounds acts independently to increase, decrease, or maintain the intensity of the wavelength or wavelength band of light. For example, one photoluminescent compound can reduce the intensity of light, while another compound can increase different light intensities. In some embodiments, the photoluminescent compounds in the light-modulating cosmetic composition can maintain light intensity by not interacting with the wavelength or preventing intensity loss. In some cases, two or more compounds modulate light of the same wavelength or wavelength band. For example, the two or more compounds modulate blue light. In some cases, the two or more compounds modulate light of different wavelengths or wavelength bands. For example, one of the two or more compounds modulates blue light and a different compound modulates red light.

[0057] In some embodiments, the light-modulating cosmetic composition comprises at least 2 different photoluminescent compounds. In some embodiments, at least one compound has an absorption peak wavelength in the range of about 380 to about 500 nm. In some embodiments, each compound has at least one absorption peak wavelength in the range of about 380 to about 500 nm. In some embodiments, at least one compound has an emission peak wavelength in the range of about 500 to about 575 nm. In some embodiments, at least one other compound has an emission peak wavelength in the range of about 575 to about 780 nm. In some embodiments, at least one compound has an emission peak wavelength in the range of about 575 to about 780 nm. In some embodiments, the light-modulating cosmetic composition comprises at least 3 different photoluminescent compounds. In some embodiments, the light-modulating cosmetic composition comprises at least one photoluminescent compound having an emission peak wavelength in the range of about 400 to about 500 nm.

[0058] In some embodiments, the photoluminescent compound includes an organic pigment. In some embodiments, the photoluminescent compound includes an inorganic pigment. In some embodiments, the photoluminescent compound includes an organic pigment and an inorganic pigment.

[0059] In some embodiments, at least one compound with an emission peak wavelength in the range of about 500 to about 575 nm is selected from octahydrocoumarin, fluorescein, eosin Y, lemon yellow, 2h-1-benzopyran-2-one, daphnetin, coumarin, 7-diethylamino-4-methylcoumarin, quinoline, artemisinin, curcumin and naphthalimide. In some embodiments, at least one compound with an emission peak wavelength in the range of about 500 to about 575 nm is selected from fluorescein and eosin Y. In some embodiments, at least one other compound with an emission peak wavelength in the range of about 575 to about 780 nm is selected from Phloxine, rhodamine B, rhodamine 6G, benzopyran and cyanine. In some embodiments, at least one other compound with an emission peak wavelength in the range of about 575 to about 780 nm is selected from Phloxine and rhodamine B. In some embodiments, the light-modulating cosmetic composition comprises at least one compound having an emission peak wavelength in the range of about 400 to about 500 nm, the at least one compound being selected from coumarin, aminocoumarin, and disulfonated stilbene derivatives. In some embodiments, the light-modulating cosmetic composition includes fluorescein, eosin Y, and fluorescein. In some embodiments, the light-modulating cosmetic composition includes fluorescein, eosin Y, CI47005, and fluorescein.

[0060] In some embodiments, the total concentration of the photoluminescent compounds in the light-modulating cosmetic composition is at least about 0.001%, 0.005%, 0.01%, 0.05%, 0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 30%, 40%, or 50% by weight of the composition. In some embodiments, the total concentration of the photoluminescent compounds in the light-modulating cosmetic composition is at least about 0.001%, 0.005%, 0.01%, 0.05%, 0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, 10%, 15%, or 20% by weight of the composition. In some embodiments, the total concentration of the photoluminescent compounds in the light-modulating cosmetic composition is at least about 0.001%, 0.01%, 0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, 10%, or 15% by weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is at least about 0.001%, 0.01%, 0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, or 10% by weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is at least about 0.001%, 0.01%, 0.1%, 0.5%, 1%, 2%, 3%, 4%, or 5% by weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in the range of about 0.001% to about 50% by weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in the range of about 0.001% to about 40% by weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in the range of about 0.001% to about 30% by weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in the range of about 0.001% to about 20% by weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in the range of about 0.001% to about 15% by weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in the range of about 0.001% to about 10% by weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in the range of about 0.001% to about 5% by weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in the range of about 0.001% to about 2% by weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in the range of about 0.001% to about 1% by weight of the composition.In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in the range of about 0.001% to about 0.5% by weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in the range of about 0.001% to about 0.1% by weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in the range of about 0.001% to about 0.01% by weight of the composition.

[0061] In some embodiments, the light-modulating cosmetic composition comprises a first photoluminescent compound that comprises from about 50% to about 100% of the total amount of photoluminescent compounds in the composition. In some embodiments, the light-modulating cosmetic composition comprises a second photoluminescent compound that comprises from about 0.0001% to about 15% of the total amount of photoluminescent compounds in the composition. In some embodiments, the light-modulating cosmetic composition comprises a third photoluminescent compound that comprises from about 0.0001% to about 15% of the total amount of photoluminescent compounds in the composition.

[0062] In some embodiments, the light-modulating cosmetic composition comprises the first photoluminescent compound and the second photoluminescent compound in a ratio of 8: 1. In some embodiments, the light-modulating cosmetic composition comprises the first, second, and third photoluminescent compounds in a ratio of 8: 1: 1. In some embodiments, the light-modulating cosmetic composition comprises the first, second, third, and fourth photoluminescent compounds in a ratio of 5: 1: 1: 1.

[0063] In some embodiments, the light modulating cosmetic composition reduces the irradiance of blue light from a non-uniform light emitting source. In some embodiments, the light modulating cosmetic composition emits orange light. For example, the light modulating cosmetic composition increases the irradiance of orange light. In some embodiments, the light modulating cosmetic composition reduces the irradiance of blue light from a non-uniform light emitting source and emits orange light, for example, increases the irradiance of orange light. In some embodiments, the blue light is within the range of about 450 nm ± about 50 nm. In some embodiments, the blue light is within the range of about 450 nm ± about 25 nm. In some embodiments, the orange light is within the range of about 600 nm ± about 50 nm. In some embodiments, the orange light is within the range of about 600 nm ± about 25 nm. In some embodiments, the reduction in blue light irradiance is at least about 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 30%, 40% or 50% compared to unmodulated irradiance. In some embodiments, the reduction in blue light irradiance is in the range of about 1% to about 50% compared to unmodulated irradiance. In some embodiments, the reduction in blue light irradiance is in the range of about 1% to about 40% compared to unmodulated irradiance. In some embodiments, the reduction in blue light irradiance is in the range of about 1% to about 30% compared to unmodulated irradiance. In some embodiments, the reduction in blue light irradiance is in the range of about 1% to about 20% compared to unmodulated irradiance. In some embodiments, the reduction in blue light irradiance is in the range of about 1% to about 15% compared to unmodulated irradiance. In some embodiments, the reduction in blue light irradiance is in the range of about 1% to about 10% compared to unmodulated irradiance. In some embodiments, the reduction in blue light irradiance is in the range of about 1% to about 5% compared to unmodulated irradiance. In some embodiments, the increase in orange light emission intensity is at least about 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 30%, 40%, or 50% compared to unmodulated emission. In some embodiments, the increase in orange light emission intensity is at least about 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 30%, or 40% compared to unmodulated emission. In some embodiments, the increase in orange light emission intensity is at least about 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 30%, or 40% compared to unmodulated emission. In some embodiments, the increase in orange light emission intensity is at least about 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, or 30% compared to unmodulated emission. In some embodiments, the increase in orange light emission intensity is at least about 1%, 2%, 3%, 4%, 5%, 10%, 15%, or 20% compared to unmodulated emission. In some embodiments, the increase in orange light irradiance is in the range of about 1% to about 50% compared to unmodulated irradiance. In some embodiments, the increase in orange light irradiance is in the range of about 1% to about 40% compared to unmodulated irradiance.In some embodiments, the increase in orange light irradiance is in the range of about 1% to about 30% compared to unmodulated irradiance. In some embodiments, the increase in orange light irradiance is in the range of about 1% to about 20% compared to unmodulated irradiance. In some embodiments, the increase in orange light irradiance is in the range of about 1% to about 15% compared to unmodulated irradiance. In some embodiments, the increase in orange light irradiance is in the range of about 1% to about 10% compared to unmodulated irradiance. In some embodiments, the light modulating cosmetic composition does not change (e.g., maintains) the irradiance at a wavelength of about 540 nm. For example, in some embodiments, the change in irradiance at a wavelength of about 540 nm is less than 5%, 4%, 3%, 2%, or 1% compared to unmodulated irradiance.

[0064] In some embodiments, the light modulating cosmetic composition comprises one or more of the following: glycerin, water (e.g., deionized water), a glycol derivative, a hydrogel, or other solvent or powder carrier acceptable for surface application. In some embodiments, the light modulating cosmetic composition comprises glycerin. In some embodiments, the light modulating cosmetic composition comprises glycerin and a hydrogel. In some embodiments, the light modulating cosmetic composition comprises one or more of the following: glycerin, an acrylate (e.g., a C10-30 alkyl acrylate cross-polymer), xanthan gum, or a triglyceride (e.g., a medium chain triglyceride). In some embodiments, the light modulating cosmetic composition comprises one or more of the following: an emollient, a humectant, a gelling agent, an emulsifier, an oil, a wax, a preservative, a fragrance, an active ingredient, a pigment, a sunscreen, a colorant, a chelating agent, or an antioxidant. In some embodiments, the light modulating cosmetic composition includes a gelling agent.

[0065] In some embodiments, the light-modulating cosmetic composition comprises one or more of glyceryl stearate, PEG (e.g., PEG-100 stearate), isononyl isononanoate, mineral oil, dimethicone, phenoxyethanol, methylparaben, ethylparaben, butylparaben, propylparaben, water, or sodium hydroxide. In some embodiments, the light-modulating cosmetic composition comprises one or more of the following: water, sodium phytate, alcohol, xanthan gum, C12-C16 alcohols, hydrogenated lecithin, palmitic acid, isoamyl laurate, shorea stenoptera seed butter, diisopropyl adipate, shea butter cetyl esters, behenyl alcohol, butyrospermum parkii (shca) unsaponifiable oil, soy bean glycerides, macadamia ternifolia seed oil, dimethicone, fragrance, helianthus annuus (sunflower) seed oil, tocopherol, phenoxyethanol, or caprylyl glycol.

[0066] In some embodiments, the light-modulating cosmetic composition comprises one or more active agents with a cosmetic effect. An active ingredient with a cosmetic effect, an active agent with a cosmetic effect, a cosmetic agent, or an active ingredient with a cosmetic effect refers to a compound that is capable of exerting at least one cosmetic effect on the skin, hair, and / or nails. A cosmetic effect means any non-therapeutic effect intended to modify and / or improve the visual appearance and mechanical properties of the skin, hair, and / or nails, such as protecting them from external aggressions (sun, wind, humidity, dryness, chemicals), preventing and / or correcting phenomena associated with their aging, or preventing or treating effects caused by stress or fatigue, inflammation. In some embodiments, the light-modulating cosmetic composition exerts a cosmetic effect independently of an additional active agent with a cosmetic effect.

[0067] Examples of such agents include, inter alia, anti-wrinkle agents, anti-aging agents, antioxidants, anti-inflammatory agents, anti-stress agents, moisturizers, soothing agents, anti-redness agents, decongestants, exfoliants or exfoliating agents, matting agents, sebum regulating agents, brightening active ingredients, anti-staining active ingredients, anti-dark circles or anti-eye bags agents, anti-stress agents, anti-fatigue agents, anti-pollution active ingredients, tensor agents, filters and sunscreens, and combinations thereof.

[0068] In some embodiments, the light-modulating cosmetic composition can include an active ingredient selected from the group consisting of anti-wrinkle agents, anti-redness agents, antioxidants, moisturizing actives, soothing agents, seboregulating agents, anti-staining or brightening agents, firming agents, anti-pollution actives, anti-dark circle or anti-eye bag agents, light filters or sunscreens, and combinations thereof.

[0069] Non-limiting examples of anti-fouling agents include extracts of Chrysanthellum Indicum polysaccharides, such as fermentation media from Alteromonas, and Nigari's salts.

[0070] Non-limiting examples of anti-eye bag agents include extracts of Chrysanthellum Indicum or sulfated polysaccharides of algae, particularly Cophyllum nodosum or Asparagopsis Armata.

[0071] Non-limiting examples of moisturizers include urea, oxyproline (PCA) and its derivatives (particularly its salts such as arginine PCA, chitosan PCA, its copper salts (PCA copper), magnesium salts (PCA magnesium), sodium salts (PCA sodium) or zinc salts, ethylhexyl PCA), calcium gluconate, hyaluronic acid and its salts and other glycosaminoglycans, frucosis, glucose, isomaltose, lactose, trehalose, polydextrose, sucrose (sucrose), maltitol, mannitol, sorbitol, xylitol and other carbohydrates and derivatives, polyethylene glycols such as PEG-7, PEG-8, PEG-10, PEG-12 or PEG-14, glycerol, propylene glycol, butylene glycol, betaine, citrulline, collagen and its derivatives, histidine, silk, keratin or soy hydrolyzate, plant extracts rich in polysaccharides and / or polyphenols such as extracts of aloe vera, blueberry (Centaurea cyanus), cyanus), extracts rich in polysaccharides (particularly from fermentation media of marine microorganisms such as Alteromonas), and combinations thereof.

[0072] Non-limiting examples of anti-aging agents include ascorbic acid and its derivatives such as magnesium ascorbyl phosphate, glycosaminoglycans and their derivatives, Cyathea polysaccharides, collagen, flaxseed extract (Linumusitatissimum), peptides such as hexanoyl-tetrapeptide-3 and trifluoroacetyl tripeptide-2, extracts of Polygonum aviculare, extracts of brown algae (particularly Ascophyllum nodosum), extracts of ferns (particularly Cyathea cumingii).

[0073] Non-limiting examples of anti-stress agents include Rosality™ products (a combination of rose water and rose essential oil) and rose labdanum extract, such as sold under the brand name IBR-Chill™.

[0074] Non-limiting examples of soothing agents include allantoin, aloe vera extract, birch (e.g., Betula alba), fireweed (Epilobium angustifolium), chestnut (e.g., Castanea sativa), blueberry (Centaurea cyanus), centella (e.g., Centella asiatica), horsetail (e.g., Equisetum arvense), fennel (e.g., Foeniculum vulgare), witch hazel (e.g., Hamamelis virginiana), ivy (e.g., Hedera helix), roselle (hibiscus sabdariffa), lily (e.g., Lilium candidum), mallow (e.g., Malva sylvestris), lemon balm (e.g., Melissa officinalis), thyme (e.g., officinalis), baicalin (e.g., Scutellaria baicalensis), mimosa (e.g., Mimosa tenuiflora), potentilla (e.g., Potentilla erecta), oligosaccharides or extracts of oligosaccharides (e.g., flax), peptides (e.g., palmitoyl tripeptide-8), extracts of polysaccharides (including extracts of exopolysaccharides from fermentation medium of Alteromonas), and combinations thereof.

[0075] Non-limiting examples of antioxidants include HMR (hydroxymethylresorcinol), ascorbic acid and its derivatives, vitamin B9, histidine hydrochloride or fireweed extract (Epilobium augustifolium). Active ingredients with antioxidant and vitamin-like effects are usually used in a mass percentage of at least 1% of the total weight of the cosmetic composition.

[0076] Non-limiting examples of sebum regulating agents include flax lignans, rice powder, zinc gluconate, sarcosine, extract of Cinnamomum zeylanicum bark, extract of avocado, extract of Backhousia citriodora, and combinations thereof.

[0077] Non-limiting examples of anti-redness agents include saponins, flavonoids, ruscogenins, esculosides, and extracts containing them, such as extracts of Ruscus, and certain essential oils, such as lavender or rosemary.

[0078] Non-limiting examples of anti-staining agents include extracts such as liquorice (Glycyrrhyza glabra), jackfruit extract (Artocarpus heterophyllus), sorrel extract (R. occidentalis), plant extracts belonging to the genus Citrus, resveratrol, peptides such as oligopeptide-68, nonapeptide-1, kojic acid, magnesium ascorbyl phosphate, and combinations thereof.

[0079] In some embodiments, the light-modulating cosmetic composition is contained in a cream, lotion, gel, foam, paste, ointment, balm, varnish, or ointment. In some embodiments, the total concentration of the photoluminescent compound contained in the cream, lotion, gel, foam, paste, ointment, balm, varnish, or ointment is at least about 0.001%, 0.005%, 0.01%, 0.05%, 0.1%, 0.5%, or 1% by weight. In some embodiments, the total concentration of the photoluminescent compound contained in the cream, lotion, gel, foam, paste, ointment, balm, varnish, or ointment is in the range of about 0.001% to about 1% by weight. In some embodiments, the total concentration of the photoluminescent compound contained in the cream, lotion, gel, foam, paste, ointment, balm, varnish, or ointment is in the range of about 0.001% to about 0.5% by weight. In some embodiments, the total concentration of photoluminescent compounds contained in a cream, lotion, gel, foam, paste, ointment, balm, varnish, or ointment is in the range of about 0.001% to about 0.1% by weight. In some embodiments, the total concentration of photoluminescent compounds contained in a cream, lotion, gel, foam, paste, ointment, balm, varnish, or ointment is in the range of about 0.001% to about 0.05% by weight. In some embodiments, the total concentration of photoluminescent compounds contained in a cream, lotion, gel, foam, paste, ointment, balm, varnish, or ointment is in the range of about 0.001% to about 0.01% by weight. In some embodiments, the total concentration of photoluminescent compounds contained in a cream, lotion, gel, foam, paste, ointment, balm, varnish, or ointment is in the range of about 0.001% to about 0.005% by weight. It should be understood that weight percentages are with respect to the weight of the composition.

[0080] In some embodiments, the light-modulating cosmetic composition modulates the irradiance of the non-uniform light-emitting source on the target tissue for at least about 1, 2, 3, 4, 5, 6, 7, 8, or more hours.

[0081] B.Consumer goods

[0082] The light modulating cosmetic composition described herein can be included in a consumer product. As used herein, the consumer product can be a face or body powder, foundation, makeup product, oil (e.g., body oil, facial oil), mousse, cream, wax, balm (e.g., lip balm), mask, paste, foam, ointment, gel, varnish, ointment, lotion (e.g., body lotion, facial lotion), spray, personal care product, nail care product, baby care product, non-aerosol body spray, body milk, body cream, sunscreen lotion, sunscreen spray, sunblock, roll-on product, aerosol product, natural spray product, hair care product, fabric care product, etc.

[0083] In some embodiments, the consumer product is a cream, lotion, gel, foam, paste, ointment, balm, varnish or ointment. In some embodiments, the consumer product is a cream. In some embodiments, the cream is an emulsion. In some embodiments, the consumer product is a lotion. In some embodiments, the consumer product is a varnish.

[0084] In some embodiments, the consumer product is a personal care product, a skin care product, a body care product, a hair care product, a makeup product, a nail care product, or a baby care product. In some embodiments, the consumer product is a skin care product. In some embodiments, the consumer product is a body care product. In some embodiments, the consumer product is a nail care product. In some embodiments, the consumer product is a baby care product.

[0085] In some embodiments, the total concentration of photoluminescent compounds contained in the consumer product is at least about 0.001%, 0.005%, 0.01%, 0.05%, 0.1% or 0.5% or 1% by weight. In some embodiments, the total concentration of photoluminescent compounds contained in the consumer product is in the range of about 0.001% to about 1% by weight. In some embodiments, the total concentration of photoluminescent compounds contained in the consumer product is in the range of about 0.001% to about 0.5% by weight. In some embodiments, the total concentration of photoluminescent compounds contained in the consumer product is in the range of about 0.001% to about 0.1% by weight. In some embodiments, the total concentration of photoluminescent compounds contained in the consumer product is in the range of about 0.001% to about 0.05% by weight. In some embodiments, the total concentration of photoluminescent compounds contained in the consumer product is in the range of about 0.001% to about 0.01% by weight. In some embodiments, the total concentration of photoluminescent compounds contained in the consumer product is in the range of about 0.001% to about 0.05% by weight. In some embodiments, the total concentration of photoluminescent compounds contained in the consumer product is in the range of about 0.001% to about 0.01% by weight. In some embodiments, the total concentration of photoluminescent compounds contained in the consumer product is in the range of about 0.001% to about 0.005% by weight. It should be understood that weight percentages are by weight of the consumer product.

[0086] II. Cosmetic methods and uses

[0087] Also provided herein are methods and uses of light-modulating cosmetic compositions and consumer products containing the light-modulating cosmetic compositions. The methods and uses provided herein include topically applying a light-modulating cosmetic composition or a consumer product to provide a beneficial effect to a target tissue and / or well-being of a subject.

[0088] In one aspect, a method of modulating irradiance from a non-uniform light emitting source on a target tissue is provided, comprising topically applying a light-modulating cosmetic composition or consumer product described herein to the target tissue.

[0089] In one aspect, a method of reducing or preventing photodamage to a target tissue from light emitted from a non-uniform light emitting source is provided, comprising topically applying a light modulating cosmetic composition or consumer product described herein to the target tissue. In some embodiments, the photodamage comprises photooxidative stress. In some embodiments, the photodamage comprises photoaging.

[0090] In one aspect, provided are methods of reducing or preventing aging of a target tissue from light emitted from a non-uniform light emitting source, comprising topically applying a light-modulating cosmetic composition or consumer product described herein to the target tissue.

[0091] In one aspect, provided are methods of reducing or preventing oxidative stress in a target tissue from light emitted from a non-uniform luminescent source, comprising topically applying a light-modulating cosmetic composition or consumer product described herein to the target tissue.

[0092] Also provided is a method for modulating the photoactivation of a chromophore in a target tissue by light emitted from a non-uniform light emitting source, comprising applying a light modulating cosmetic composition or consumer product surface as described herein to the target tissue. In some embodiments, the chromophore is water. In some embodiments, the chromophore is an opsin. In some embodiments, the opsin is contained in a photoreceptor. In some embodiments, the photoreceptor is present in the target tissue. In some embodiments, the opsin is opsin 1SW. In some embodiments, the opsin is opsin 2. In some embodiments, the opsin is opsin 1SW and opsin 2. In some embodiments, the chromophore is cytochrome C oxidase (CCO). In some embodiments, CCO is contained in mitochondria.

[0093] In some embodiments, modulating the photoactivation of the chromophore comprises increasing or decreasing the photoactivation of the chromophore. In some embodiments, modulating the photoactivation of the chromophore comprises stimulating a biological response in a target tissue. In some embodiments, the biological response comprises one or more of restoring or maintaining an activity level, increasing an activity level, or decreasing an activity level. Restoring activity refers to reaching an activity level observed before exposure (optionally repeated exposure) to a non-uniform light emitting source. Maintaining an activity level refers to maintaining an activity level after exposure (optionally repeated exposure) to a non-uniform light emitting source. Increasing an activity level refers to increasing an activity level that should be maintained or decreased in response to exposure (optionally repeated exposure) to a non-uniform light emitting source. Reducing an activity level refers to reducing an activity level that should be maintained or increased in response to exposure (optionally repeated exposure) to a non-uniform light emitting source. In some embodiments, the increase in activity includes an increase of at least or about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, including all values ​​falling between these percentages, in the expression of the activity prior to use of a composition described herein. In some embodiments, the increase in activity includes an increase of at least or about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, including all values ​​falling between these percentages, in the expression of activity relative to the activity in a subject not using a composition described herein and exposed to the same conditions.In some embodiments, the decrease in activity includes at least or about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, including all values ​​falling between these percentages, in the expression of the activity prior to use of a composition described herein. In some embodiments, the decrease in activity includes at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% (including all values ​​falling between these percentages) or about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% (including all values ​​falling between these percentages). In some embodiments, maintaining activity includes no more than about 15% change in the expression of activity before using the composition described herein. In some embodiments, maintaining activity includes no more than about 15% change in the expression of activity relative to the activity in subjects not using the composition described herein and exposed to the same conditions. In some embodiments, maintaining activity includes no more than about 10% change in the expression of activity before using the compositions described herein. In some embodiments, maintaining activity includes no more than about 10% change in the expression of activity relative to the activity in subjects not using the compositions described herein and exposed to the same conditions. In some embodiments, maintaining activity includes no more than about 5% change in the expression of activity before using the compositions described herein. In some embodiments, maintaining activity includes no more than about 5% change in the expression of activity relative to the activity in subjects not using the compositions described herein and exposed to the same conditions.

[0094] In some embodiments, the biological response is cell communication activity. In some embodiments, cell communication activity increases. In some embodiments, the biological response is photoreceptor expression activity. In some embodiments, photoreceptor expression activity is increased expression of opsin 2. In some embodiments, photoreceptor expression activity is decreased expression of opsin 1SW. In some embodiments, the biological response is mitochondrial activity. In some embodiments, mitochondrial activity is maintained or restored. Methods for measuring biological activities of interest are known in the art, and non-limiting examples of such methods contemplated herein are described in Section V.

[0095] On the one hand, a method for improving the appearance of a target tissue exposed to light emitted from a non-uniform light source is provided, comprising applying a light modulating cosmetic composition or consumer product surface as described herein to the target tissue. In some embodiments, the improvement includes reducing or preventing the roughness of the target tissue or maintaining the smoothness of the target tissue. In some embodiments, the improvement includes reducing or preventing wrinkles or fine lines in the target tissue. In some embodiments, the target tissue is the skin under the eyes, and the improvement includes reducing the appearance of dark circles in the target tissue. In some embodiments, the improvement includes reducing or preventing the redness of the target tissue. Redness can be a sign of tissue inflammation. Therefore, in some cases, the improvement includes reducing or preventing the inflammatory response in the target tissue. In some embodiments, the improvement includes increasing or maintaining the gloss and / or brightness of the target tissue. Maintaining refers to maintaining an activity level or condition after exposure to or repeated exposure to a non-uniform light source as described above. Increasing refers to increasing the activity level or condition that should be maintained or reduced in response to exposure to a non-uniform light source as described above.

[0096] In one aspect, methods are provided for improving the well-being of a subject exposed to light emitted from a non-uniform luminescent source, comprising topically applying a light-modulating cosmetic composition or consumer product as described herein to a target tissue. In some embodiments, the improvement comprises a reduction in emotional stress levels, e.g., compared to emotional stress levels recorded prior to use or compared to emotional stress levels that would have been achieved if use had not occurred. In some embodiments, the improvement comprises an increase in chakra energy, e.g., compared to energy levels recorded prior to use or compared to energy levels that would have been achieved if use had not occurred. Methods for assessing stress and chakra energy levels are known in the art, and non-limiting examples of such methods are described in Section V. Levels and measurements for determining increase, decrease, or maintenance are as described above.

[0097] The target tissue described herein can be any human tissue. In some embodiments, the target tissue is any tissue exposed to a non-uniform light source. In some embodiments, the target tissue is skin. In some embodiments, the target tissue is facial skin. In some embodiments, the target tissue is skin under the eyes. In some embodiments, the target tissue is hair. In some embodiments, the target tissue is nails.

[0098] The dose and frequency of application of the light-modulating cosmetic composition or consumer product to be applied vary depending on the desired cosmetic effect, individual characteristics such as gender, age, hair type, and skin type. In some embodiments, the light-modulating cosmetic composition or consumer product can be applied to the area to be treated once a day, twice a day (e.g., morning and evening) for several consecutive weeks or even months, for example, for at least 3, 6, 9 months. For example, a subject can apply a 1 g to 2 g dose of the cosmetic composition or consumer product to their face in the evening or morning and evening.

[0099] III. Methods of Preparing Consumer Products

[0100] In one aspect, a method for preparing a consumer product (such as the consumer product described in Section IB) is provided, comprising adding the light modulating cosmetic composition described herein to a cosmetic base to form a mixture, and (b) stirring the mixture to achieve homogeneity. In some embodiments, the mixture is emulsified. In some embodiments, the mixture is cooled. In some embodiments, the mixture is pH adjusted.

[0101] In some embodiments, the cosmetic base includes one or more of the following: water, emollients, humectants, gelling agents, emulsifiers, oils, waxes, butters, surfactants, preservatives, fragrances, active ingredients, pigments, sunscreens, colorants, chelating agents, or antioxidants.

[0102] In some embodiments, the method comprises adding one or more of the following: an anti-wrinkle agent, an anti-aging agent, an antioxidant, a moisturizer, a soothing agent, an anti-redness agent, a decongestant, an exfoliant or exfoliating agent, a matte agent, a sebum regulating agent, a brightening active ingredient, an anti-pollution active ingredient, an anti-dark circle or anti-eye bag agent, an anti-stress agent, an anti-fatigue active ingredient, an anti-pollution active ingredient, a firming agent, a light filter, or a sunscreen.

[0103] IV. Kit

[0104] Also provided are kits comprising the light-modulating cosmetic compositions described herein, which may further include instructions for methods of using the compositions, such as the uses described herein. The kits described herein may also contain other materials desirable from a commercial and user perspective, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for performing any of the methods described herein.

[0105] V. Exemplary Embodiments

[0106] The embodiments provided are:

[0107] 1. A light-modulating cosmetic composition comprising one or more photoluminescent compounds, wherein the composition modulates the irradiance of a non-uniform light-emitting source on a target tissue.

[0108] 2. The light-modulating cosmetic composition of embodiment 1, wherein the composition modulates the intensity of light in one or more of the ultraviolet spectrum, visible spectrum, or infrared spectrum emitted by a non-uniform light emitting source.

[0109] 3. The light-modulating cosmetic composition of embodiment 2, wherein modulation independently comprises increasing, decreasing or maintaining the intensity of the light.

[0110] 4. The light-modulating cosmetic composition of any one of embodiments 1 to 3, wherein the composition modulates the irradiance of a non-uniform light emitting source to produce white light.

[0111] 5. The light-modulating cosmetic composition of any one of embodiments 1 to 4, wherein the composition comprises at least 2 different photoluminescent compounds, each compound having at least one absorption peak wavelength in the range of about 380 to about 500 nm, at least one compound having an emission peak wavelength in the range of about 500 to about 575 nm, and at least one other compound having an emission peak wavelength in the range of about 575 to about 780 nm.

[0112] 6. The light-modulating cosmetic composition of any one of embodiments 1 to 5, wherein the composition comprises at least 3 different photoluminescent compounds.

[0113] 7. The light-modulating cosmetic composition of any one of embodiments 1 to 6, wherein the composition comprises at least one photoluminescent compound having an emission peak wavelength in the range of about 400 to about 500 nm.

[0114] 8. The light-modulating cosmetic composition of any one of embodiments 1 to 7, wherein the photoluminescent compound is an organic pigment and / or an inorganic pigment.

[0115] 9. The light-modulating cosmetic composition of any one of embodiments 1 to 8, wherein:

[0116] - at least one compound having an emission peak wavelength in the range of about 500 to about 575 nm selected from octahydrocoumarin, fluorescein, eosin Y, tartrazine, 2h-1-benzopyran-2-one, daphnetin, coumarin, 7-diethylamino-4-methylcoumarin, quinoline, artemisinin, curcumin and naphthalimide; and / or

[0117] - at least one other compound having an emission peak wavelength in the range of about 575 to about 780 nm selected from the group consisting of fluorescein, rhodamine B, rhodamine 6G, benzopyran and cyanine.

[0118] 10. The light-modulating cosmetic composition of any one of embodiments 1 to 9, wherein the composition comprises at least one compound having an emission peak wavelength in the range of about 400 to about 500 nm, the at least one compound being selected from coumarin, aminocoumarin, and disulfonate stilbene derivatives.

[0119] 11. The light-modulating cosmetic composition of any one of embodiments 1 to 10, wherein the total concentration of the photoluminescent compounds in the composition is in the range of about 0.001% to about 20% by weight of the composition.

[0120] 12. The light-modulating cosmetic composition of any one of embodiments 1 to 11, wherein the composition comprises a first photoluminescent compound, the first photoluminescent compound accounting for about 50% to about 100% of the total amount of photoluminescent compounds in the composition, and the second photoluminescent compound accounting for about 0.0001% to about 15% of the total amount of photoluminescent compounds in the composition.

[0121] 13. The light-modulating cosmetic composition of any one of embodiments 1 to 12, wherein the composition comprises a third photoluminescent compound, the third photoluminescent compound accounting for about 0.0001% to about 15% of the total amount of photoluminescent compounds in the composition.

[0122] 14. The light-modulating cosmetic composition of any one of embodiments 1 to 13, wherein the composition comprises one or more of the following: glycerin, water, glycol derivatives, hydrogels, or other solvents or powder carriers acceptable for topical application.

[0123] 15. The light-modulating cosmetic composition of any one of embodiments 1 to 14, wherein the composition comprises one or more of the following: an emollient, a humectant, a gelling agent, an emulsifier, an oil, a wax, a preservative, a fragrance, an active ingredient, a pigment, a sunscreen, a colorant, a chelating agent, or an antioxidant.

[0124] 16. The light-modulating cosmetic composition of any one of embodiments 1 to 15, wherein the composition is contained in a cream, lotion, gel, foam, paste, salves, balms, varnish or ointment.

[0125] 17. The light modulating composition of embodiment 15 or embodiment 16, wherein the total concentration of the photoluminescent compounds in the composition is in the range of about 0.001% to about 0.1% by weight.

[0126] 18. The light-modulating cosmetic composition of any one of embodiments 1 to 17, wherein the composition reduces the irradiance of blue light from a non-uniform light emitting source on a target tissue, and optionally emits orange light.

[0127] 19. The light-modulating cosmetic composition of any one of embodiments 1 to 18, wherein the non-uniform light emitting source is one or more of the following: a computer, a tablet computer, a mobile phone, a television, a fluorescent lamp, a light emitting diode (LED), or any other digital device or artificial light source comprising a light source that emits non-uniform light, optionally wherein at least one non-uniform emission wavelength is in the blue light spectrum.

[0128] 20. The light-modulating cosmetic composition of any one of embodiments 1 to 19, wherein the composition modulates the irradiance of the non-uniform light-emitting source on the target tissue for at least about 1, 2, 3, 4, 5, 6, 7, 8, or more hours.

[0129] 21. The light-modulating cosmetic composition of any one of embodiments 1 to 20, wherein the target tissue is skin, optionally facial skin, hair and / or nails.

[0130] 22. A consumer product comprising the light-modulating cosmetic composition of any one of embodiments 1 to 21, wherein the consumer product is a cream, lotion, gel, foam, paste, salve, balm, varnish or ointment.

[0131] 23. The consumer product of embodiment 22, wherein the consumer product is a skin care product, a body care product, a hair care product, a makeup product, a nail care product or a baby care product.

[0132] 24. The consumer product of embodiment 22 or embodiment 23, wherein the total concentration of the photoluminescent compound in the consumer product is in the range of about 0.001% to about 0.1% by weight of the consumer product.

[0133] 25. A method of modulating irradiance from a non-uniform light emitting source on a target tissue, comprising topically applying the light modulating cosmetic composition of any one of embodiments 1 to 21 or the consumer product of any one of embodiments 22 to 24 to the target tissue.

[0134] 26. A method of reducing or preventing photodamage to a target tissue from light emitted from a non-uniform light emitting source, comprising topically applying the light-modulating cosmetic composition of any one of embodiments 1 to 21 or the consumer product of any one of embodiments 22 to 24 to the target tissue.

[0135] 27. The method of embodiment 26, wherein the photodamage comprises photoinduced oxidative stress.

[0136] 28. The method of embodiment 26 or embodiment 27, wherein photodamage comprises photoaging.

[0137] 29. A method of reducing or preventing aging of a target tissue from light emitted from a non-uniform light emitting source, comprising topically applying the light modulating cosmetic composition of any one of embodiments 1 to 21 or the consumer product of any one of embodiments 22 to 24 to the target tissue.

[0138] 30. A method of reducing or preventing oxidative stress in a target tissue from light emitted from a non-uniform luminescent source, comprising topically applying the light-modulating cosmetic composition of any one of embodiments 1 to 21 or the consumer product of any one of embodiments 22 to 24 to the target tissue.

[0139] 31. A method of modulating photoactivation of chromophores in a target tissue by light emitted from a non-uniform light emitting source, comprising topically applying the light modulating cosmetic composition of any one of embodiments 1 to 21 or the consumer product of any one of embodiments 22 to 24 to the target tissue.

[0140] 32. The method of embodiment 31, wherein the chromophore comprises one or more of the following: water, opsin, or cytochrome C oxidase (CCO).

[0141] 33. The method of embodiment 31 or embodiment 32, wherein the chromophore is an opsin contained in a photoreceptor, optionally wherein the opsin is opsin 1SW and / or opsin 2.

[0142] 34. The method of any one of embodiments 31 to 33, wherein the chromophore is CCO contained in mitochondria.

[0143] 35. The method of any one of embodiments 31 to 34, wherein modulating the photoactivation of the chromophore comprises increasing or decreasing the photoactivation of the chromophore.

[0144] 36. The method of any one of embodiments 31 to 35, wherein photoactivation of the modulated chromophore comprises stimulating a biological response in the target tissue, wherein the biological response comprises one or more of: restoring or maintaining an activity level, increasing an activity level, or decreasing an activity level.

[0145] 37. The method of embodiment 36, wherein the biological response comprises one or more of the following: cell communication activity, photoreceptor expression activity, or mitochondrial activity.

[0146] 38. A method of improving the appearance of a target tissue exposed to light emitted from a non-uniform light emitting source, comprising topically applying the light-modulating cosmetic composition of any one of embodiments 1 to 21 or the consumer product of any one of embodiments 22 to 24 to the target tissue.

[0147] 39. The method of embodiment 38, wherein improving comprises reducing or preventing roughness of the target tissue or maintaining smoothness of the target tissue.

[0148] 40. The method of embodiment 38 or embodiment 39, wherein the improvement comprises reducing or preventing wrinkles and fine lines in the target tissue.

[0149] 41. The method of any one of embodiments 38 to 40, wherein the target tissue is under-eye skin, and improving comprises reducing the appearance of dark circles in the target tissue.

[0150] 42. The method of any one of embodiments 38 to 41, wherein improving comprises reducing or preventing redness of the target tissue.

[0151] 43. The method of any one of embodiments 38 to 42, wherein improving comprises increasing or maintaining the glossiness and / or brightness of the target tissue.

[0152] 44. A method of improving the well-being of a subject exposed to light emitted from a non-uniform light emitting source, comprising topically applying the light-modulating cosmetic composition of any one of embodiments 1 to 21 or the consumer product of any one of embodiments 22 to 24 to a target tissue.

[0153] 45. The method of embodiment 44, wherein the improvement comprises reducing the pressure.

[0154] 46. ​​The method of embodiment 44 or embodiment 45, wherein the improvement comprises increasing chakra energy.

[0155] 47. The method of any one of embodiments 25 to 46, wherein the non-uniform light emitting source is one or more of the following: a computer, a tablet computer, a mobile phone, a television, a fluorescent lamp, a light emitting diode (LED), or any other digital device or artificial light source comprising a light source that emits non-uniform light, optionally wherein at least one non-uniform emission wavelength is in the blue light spectrum.

[0156] 48. The method of any one of embodiments 25 to 47, further comprising exposing the target tissue to a natural light source.

[0157] 49. The method of any one of embodiments 25 to 48, wherein the target tissue is skin, optionally facial skin, hair and / or nails.

[0158] 50. A method for preparing a consumer product, comprising: (a) adding a light-modulating cosmetic composition of any one of embodiments 1 to 21 to a cosmetic base to form a mixture; (b) stirring the mixture to achieve homogeneity; (c) optionally emulsifying the mixture; (d) optionally cooling the mixture; and (e) optionally adjusting the pH of the mixture.

[0159] 51. The method of embodiment 50, wherein the cosmetic base comprises one or more of the following: water, emollients, humectants, gelling agents, emulsifiers, oils, waxes, preservatives, fragrances, active ingredients, pigments, sunscreens, colorants, chelating agents, or antioxidants.

[0160] 52. A kit comprising the light-modulating cosmetic composition according to any one of embodiments 1 to 21, and instructions for use.

[0161] VI. Examples

[0162] The following examples are included for illustrative purposes and are not intended to limit the scope of the invention.

[0163] Example 1: Evaluation of Optical Properties of Photoluminescent Compounds

[0164] A mixture of three different photoluminescent compounds (fluorescent xanthenic dyes Eosin Y, fluorescein and fluorescein) was dissolved in glycerol at 0.4%. The photoluminescent mixture was dissolved in a clear gel at 1% (test mixture; see Table E1) to evaluate the fluorescence and photoconversion properties of the photoluminescent compounds in vitro.

[0165] Table E1 : Clear gel test composition.

[0166]

[0167] A. Absorption and emission spectra

[0168] Absorption spectra were recorded by UV-Vis spectrophotometer Cary 5E. Emission spectra (excitation at 455 nm) were recorded with a fluorescence spectrometer (Fluorolog FL-3).

[0169] like Figure 1 As shown in , the test mixture exhibits fluorescent properties, absorbing light between 400 nm and 550 nm and re-emitting at higher wavelengths. When exposed to a wavelength of 455 nm, the test mixture converts monochromatic light into the 500-600 nm range, producing an overall orange light emission.

[0170] B. Optical characteristics under digital screen illumination

[0171] To evaluate the efficacy of the photoluminescent mixture in the gel, according to Figure 2 Illuminance (lux) measurements were performed using the setup shown in Figure 2. Test compounds or placebo were added at 2 mg / cm 2 Spread on a transparent PVC foil placed 30 cm away from a computer screen or smartphone screen. An illuminance meter (CL70F Konica Minolta) is located immediately behind the PVC foil and measures the illuminance of the digital screen light transmitted by the gel. This design mimics the average distance between the screen and the facial skin when a person works at a computer.

[0172] The emission through the screen of the test mixture and placebo was recorded from 380 nm to 780 nm in the dark, near a window (natural light conditions) and under artificial light (LED panel). The illuminance meter records the illuminance (expressed in lux), which represents the luminous flux (in lumens) received per surface unit (in m²). This measurement represents the amount of incident light illuminating the surface.

[0173] Depending on the wavelength, the conversion between lux and W / m² can be obtained based on the spectral distribution: Illuminance = radiant flux x S, where S is the correction factor obtained with the spectral distribution (ISO 18526-2). Irradiance (in W.m².nm -1 The S factor (expressed in lux) represents the radiant flux of light received by a surface. It is the power received per unit area on a determined surface at a given moment. For example, the S factor at 455 nm is equal to 0.2667. Therefore, a radiant flux of 1 W / m² at this wavelength corresponds to 0.2667 lux.

[0174] The computer screen emission shows an irregular spectrum with 3 different peaks. Figure 3 As shown in , the main peak is located at 450-455 nm, in the mid-blue range, and corresponds to the absorption range of the photoluminescent compound. Two other peaks with lower intensity are located at 540 nm and 590 nm.

[0175] When illuminated by a computer screen at 30 cm, the test mixture was able to reduce irradiance at 450 nm by up to -16% ( Figure 4A At the same time, the test mixtures provided an increase in irradiance at 600 nm, especially under natural light and dark conditions (up to +7 %) ( Figure 4A ). The effect on the medium wavelength of 540 nm is negligible. Similar results were observed when irradiated with a smartphone screen at a distance of 30 cm ( Figure 4B ).

[0176] As shown in Tables E2 and E3, the distance of the digital screen also affects the modulation of the irradiance. Experiments to evaluate the effect of screen distance were conducted in the presence of a combination of natural and artificial light to simulate a "classic office" environment.

[0177] Table E2: Irradiance (W / m2) at 450 nm, 540 nm and 600 nm when illuminated by a computer screen at different distances (cm) under “classic office” conditions 2 ).

[0178]

[0179] Table E3: Irradiance (W / m2) at 450 nm, 540 nm and 600 nm when illuminated by a smartphone screen at different distances (cm) under “classic office” conditions 2 ).

[0180]

[0181] The duration of the effect of the photoluminescent compound mixture on irradiance was evaluated by illuminating the test mixture with a computer screen at 30 cm and measuring the irradiance at 450 nm, 540 nm and 600 nm every hour for 8 hours. Figure 4C-4E As shown, for each wavelength, the measured irradiance varies by about 10% or less, which demonstrates the stability of the effect of the photoluminescent compound.

[0182] These data support the ability of photoluminescent compound mixtures to modulate the irradiance of light emitted from non-uniform light emitting sources. These data demonstrate the ability of photoluminescent compound mixtures to absorb harmful blue light from such light sources and increase the irradiance at higher (longer) wavelengths without affecting the mid-range wavelengths. This modulation results in a more balanced irradiance across wavelengths. These data further support the stability of the photoluminescent compound effect.

[0183] Example 2: Evaluation of the Effects of Photoluminescent Compounds on Skin Explants

[0184] Exposure of human skin to blue light is known to induce severe skin damage, leading to premature aging, wrinkles, etc. Skin explants were used to evaluate the effects of photoluminescent compounds on DNA oxidation, cytochrome c oxidase activity, and opsin expression in human skin exposed to blue light.

[0185] A total of 30 human skin biopsies were obtained from plastic surgery patients (Caucasian females, 32 years old). Each explant was maintained in survival medium for 8 days and was treated daily with 1% paraformaldehyde from Solarbox. The blue light of the device (59 W / m², 455 nm) corresponds to a radiation dose of 63.75 J / cm² for 3 hours. Before irradiation, the test mixture or placebo (see Table E1 of Example 1) was applied to the surface on day 0 (D0), D1, D4 and D6. The untreated, unexposed group and the untreated, exposed group served as controls. At D8, the explants were fixed and directly frozen for 8-OHdG and opsin immunostaining.

[0186] A. DNA oxidation

[0187] 8-Hydroxydeoxyguanosine (8-OHdG) is one of the major forms of free radical-induced oxidative lesions in humans. This stable oxidatively modified DNA product reflects the extent of DNA oxidative damage. DNA oxidation in explants was detected by labeling 8-OHdG with a monoclonal anti-8-OHdG antibody conjugated to biotin and revealed by a peroxidase substrate.

[0188] Compared to the untreated unexposed condition, the percentage of 8-OHdG staining in the untreated and placebo conditions exposed to blue increased by +113% and +118%, respectively ( Figure 5 ). In contrast, the test mixture reduced staining for 8-OHdG by 89% compared to placebo.

[0189] These data support the ability of photoluminescent compounds to reduce blue light-induced DNA oxidation.

[0190] B. Cytochrome c oxidase (CCO) activity

[0191] In cells, the main function of mitochondria is to generate most of the chemical energy required for the biochemical reactions that drive cells. Most of this mechanism is located in the inner mitochondrial membrane, and includes four electron transfer chain complexes (complex I, II, III and IV), ATP synthase (complex V) ubiquinone and cytochrome c as an electron carrier. Complex IV or cytochrome c oxidase (CCO) is the terminal enzyme of the electron transport chain, which involves cytochrome c being reduced to oxygen to produce H2O and involves complex V activation to synthesize ATP. In addition, the respiratory chain of mitochondria contributes to the production of intracellular ROS (reactive oxygen species). All mitochondrial activities are sensitive to light exposure, because mitochondria contain photosensitive chromophores (such as CCO), which can be activated or inhibited by light in the visible range. Known blue light exposure increases ROS production by removing the modulation of CCO activity, which causes skin damage.

[0192] To evaluate cytochrome c oxidase (CCO) activity, frozen skin explants were lysed using an ultrasound system and the supernatant was collected after centrifugation for evaluation by an enzymatic method based on the measurement of the oxidation rate of reduced cytochrome c by means of CCO activity.

[0193] like Figure 6 As shown in Figure 2, blue light exposure increased CCO activity by 96% and 114.5% in the untreated and placebo conditions, respectively, compared to the untreated condition without blue light. However, the test mixture restored the effect of blue light on CCO activity, decreasing it by 81% ( Figure 6 ).

[0194] These data support the ability of photoluminescent compounds to reduce blue light-induced CCO activity.

[0195] C. Opsin Expression

[0196] Opsin 1SW and opsin 2 receptors are expressed on the surface of the skin, and their expression is sensitive to light excitation. These skin photoreceptors are sensitive to light absorbed by the skin, and each opsin has a different absorption spectrum and signal transduction, and their expression depends on the skin's exposure to light. It has been found that epidermal expression of opsin 1SW and opsin 2 increases after exposure to wavelengths between 355 nm and 470 nm and at 500 nm.

[0197] To detect opsin 1SW and opsin 2 expression in skin explants treated as described above, opsins were labeled with polyclonal anti-opsin 1SW and monoclonal anti-opsin 2 (both revealed by A488 secondary antibody), respectively, and then stained using ImageJ. Software was used for quantification by image analysis ( Figures 7A-7C ).

[0198] like Figures 7A-7C As shown in Figure 2, in both the untreated and placebo-exposed groups, opsin 1SW levels increased and opsin 2 levels decreased compared to untreated, unexposed controls. However, in the presence of the test mixture, opsin 1SW expression decreased by 22% and opsin 2 increased by 12% compared to placebo ( Figure 7C ).

[0199] These results support the ability of photoluminescent compounds to modify the spectrum of incident light, which protects the skin from the effects of blue light and allows the photosensitive molecules to activate until light is re-emitted at a higher wavelength.

[0200] Example 3: Evaluation of the Effects of Photoluminescent Compounds on Cellular Communication

[0201] On average, 60% of our bodies are made up of water, including our intracellular and extracellular fluids. Water is the interface, environment and support for the interaction between cells and biofields. Therefore, water is alive, dynamic, highly mobile, and able to transmit important information to living cells. In living organisms, water is structured due to the presence of electromagnetic fields, which come from the products of electrical activity produced by several different types of cells (including neurons, endocrine cells and muscle cells), but also include entities exhibited in the skin (such as sweat glands). Structured water refers to an increase in the number of aggregated hydrogen and oxygen atoms that form clusters containing 2 to hundreds of water molecules, and due to this ability to transfer protons and electrons, this structured water is a kind of energy regulator. In fact, structured water is described as a carrier involved in the transmission of biological information.

[0202] To evaluate the ability of photoluminescent compounds to increase bioinformation transmission, 0.00015% of the photoluminescent mixture (see Example 1) was mixed with ultrapure water, which was heated to less than 10°C by using the Poyinting carrier method. -4 Electromagnetization was performed at 10 nanotesla for 5 min. After exposure to blue light at 482 nm, the emission spectrum of the photoluminescent mixture was evaluated at 506 nm using a spectrophotometer. In parallel, a drop of the water mixture was evaporated in a desiccator at room temperature for 2 days, then exposed to blue light at 482 nm, and the water structuring was observed using an epifluorescence microscope (objective 40X).

[0203] After blue light exposure, the conversion of blue light at 512 nm increased by 31% ( Fig. 8A ). The results showed that the electromagnetic field improved the properties of the photoluminescent compounds. Using epifluorescence microscopy, the photoluminescent compounds followed the path of structured water ( Figures 8B-8C ).

[0204] These results suggest that photoluminescent compounds have the ability to improve cellular communication by combining their own energy with that generated by structured water.

[0205] Example 4: Visualization of photoconversion by photoluminescent compounds

[0206] The ability of photoluminescent compounds to absorb blue light and emit at higher wavelengths has been evaluated in clinical studies.

[0207] Healthy volunteers were administered the clinical test compound and clinical placebo following a randomized half-face design (see Table E4). For whole-face hyperspectral analysis, emission at 560 nm was recorded immediately and 10 min after blue light excitation at 405 nm. Negative controls were performed without blue light exposure.

[0208] Table E4: Gel-cream test compositions used in clinical studies.

[0209]

[0210] In the absence of blue light exposure, no emission at 560 nm was observed, whereas upon excitation with blue light (405 nm), the receiving half of the test mixture emitted light at 560 nm ( Fig. 9A ). By grayscale evaluation, it was observed that the emission at 560 nm under exposure to blue light increased by 73% and 96.5% on the forehead and cheeks immediately after application of the test mixture compared to the placebo. This effect was maintained over time. Fig. 9B As shown, a 77% and 94% increase was observed on the forehead and cheek, respectively, 10 minutes after application compared to the placebo side.

[0211] These data support the ability of the photoluminescent compounds to absorb blue light and re-emit at higher wavelengths when applied to a surface. These data further suggest that the photoluminescent compounds can maintain this ability over time.

[0212] Example 5: Evaluation of Photoluminescent Compounds on Skin Appearance

[0213] The effect of photoluminescent compounds on skin appearance was investigated in a clinical study involving healthy volunteers who spent time in front of a light source emitting blue light.

[0214] A multiracial group of 37 healthy female and male volunteers (30 to 50 years old) who spent at least 6 hours a day working on a computer without a blue light filter and who did not wear glasses were recruited. The volunteers were divided into 2 groups and applied the clinical test mixture or clinical placebo twice a day, morning and evening (see Example 4, Table E4). At D28, the color of the dark circles of the volunteers was evaluated by measuring the ITA° parameter using Visia-CR, and the Corneofix Analysis of the antioxidant potential of the skin by Visia-CR RBX The redness of the skin was evaluated, the glossiness of the skin was measured by spectrophotometer CM-700D, and the wrinkle volume and roughness were assessed by primo 3D.

[0215] like Figures 10A-10B As shown, at 28 days, the clinical test mixture lightened the color of dark circles by 12.5% ​​and increased antioxidant potential by 14% compared to clinical placebo. Fig. 10D ) and glossiness ( Fig. 10C) evaluation showed a decrease of 18% and an increase of 41.5%, respectively. These results support the ability of the photoluminescent compound to increase the appearance of skin health and protect the skin. In addition, since these skin parameters are associated with the appearance of skin age, the application of the clinical test mixture reduced the volume of skin wrinkles by 13.5% and the skin roughness by 8% ( Figures 10E-10F ).

[0216] These clinical results demonstrate the beneficial effects of photoluminescent compounds on skin appearance, skin protection and reduction of skin aging. These results suggest that the conversion of blue light to higher wavelengths achieved by photoluminescent compounds can protect and restore skin integrity.

[0217] Example 6: Assessment of well-being by photoluminescent compounds

[0218] The photoluminescent compounds were evaluated for their ability to affect the well-being of the subjects.

[0219] Stress and chakra energy were assessed in a multiethnic group of 15 healthy female and male volunteers (30 to 50 years old) who spent at least 6 hours a day working on a computer without a blue light filter and who did not wear glasses. The volunteers were divided into 2 groups and applied the clinical test mixture or clinical placebo twice a day, morning and evening (see Example 4, Table E4). On D28, the Biowell Assess each volunteer's stress and chakra energy.

[0220] like Figures 11A-11C As shown, there was a 42.5% reduction in stress and an increase in all chakra energies in volunteers who applied the clinical test mixture compared to volunteers who applied the clinical placebo. Overall, chakra energies increased by 25.5% compared to clinical placebo measures.

[0221] These results support that photoluminescent compounds can convert blue light emitted by screen devices or other artificial light sources into a more balanced light with higher wavelength emissions and that this has a positive effect on well-being.

[0222] The present invention is not intended to be limited to the scope of specific disclosed embodiments, which are provided to, for example, illustrate various aspects of the present invention. From the description and teachings herein, various modifications to the described compositions and methods will become apparent. Such changes can be practiced without departing from the true scope and spirit of the present disclosure, and these changes are intended to fall within the scope of the present disclosure. Although the present invention can be described in conjunction with specific preferred embodiments, it should be understood that the claimed invention should not be unduly limited to such specific embodiments. In fact, various modifications to the described modes for implementing the present invention that are apparent to those skilled in the art of chemistry, cosmetics, optics, physics, and related fields are intended to fall within the scope of the following claims.

Claims

1. A light-modulating cosmetic composition comprising one or more photoluminescent compounds, wherein the composition modulates the irradiance of a non-uniform light-emitting source on a target tissue, optionally wherein the target tissue is skin, hair and / or nails.

2. The light-modulating cosmetic composition of claim 1, wherein the composition modulates the irradiance of the non-uniform light emitting source to produce white light.

3. The light-modulating cosmetic composition of claim 1 or claim 2, wherein the composition comprises at least 2 different photoluminescent compounds, each compound having at least one absorption peak wavelength in the range of about 380 to about 500 nm, at least one compound having an emission peak wavelength in the range of about 500 to about 575 nm, and at least one other compound having an emission peak wavelength in the range of about 575 to about 780 nm.

4. The light-modulating cosmetic composition of any one of claims 1 to 3, wherein the composition comprises at least 3 different photoluminescent compounds.

5. The light-modulating cosmetic composition of any one of claims 1 to 4, wherein the composition comprises at least one photoluminescent compound having an emission peak wavelength in the range of about 400 to about 500 nm.

6. The light modulating cosmetic composition according to any one of claims 1 to 5, wherein: - at least one compound having an emission peak wavelength in the range of about 500 to about 575 nm selected from octahydrocoumarin, fluorescein, eosin Y, tartrazine, 2h-1-benzopyran-2-one, daphnetin, coumarin, 7-diethylamino-4-methylcoumarin, quinoline, artemisinin, curcumin and naphthalimide; and / or - at least one other compound having an emission peak wavelength in the range of about 575 to about 780 nm selected from the group consisting of fluorescein, rhodamine B, rhodamine 6G, benzopyran and cyanine.

7. The light-modulating cosmetic composition of any one of claims 1 to 6, wherein the composition comprises at least one compound having an emission peak wavelength in the range of about 400 to about 500 nm, the at least one compound being selected from coumarin, aminocoumarin, and disulfonate stilbene derivatives.

8. The light-modulating cosmetic composition of any one of claims 1 to 7, wherein the total concentration of photoluminescent compounds in the composition ranges from about 0.001% to about 20% by weight of the composition.

9. The light-modulating cosmetic composition of any one of claims 1 to 8, wherein the composition comprises one or more of glycerin, water, glycol derivatives, hydrogels, or other solvents or powder carriers acceptable for topical application.

10. The light-modulating cosmetic composition of any one of claims 1 to 9, wherein the non-uniform light emitting source is one or more of the following: a computer, a tablet computer, a mobile phone, a television, a fluorescent lamp, a light emitting diode (LED), or any other digital device or artificial light source that contains a light source that emits non-uniform light, optionally wherein at least one non-uniform emission wavelength is in the blue light spectrum.

11. A consumer product comprising the light-modulating cosmetic composition of any one of claims 1 to 10, wherein the consumer product is a cream, lotion, gel, foam, paste, salve, balm, varnish or ointment.

12. The consumer product of claim 11, wherein the consumer product is a skin care product, a body care product, a hair care product, a makeup product, a nail care product, or a baby care product.

13. The consumer product of claim 11 or claim 12, wherein the total concentration of the photoluminescent compound in the consumer product is in the range of about 0.001% to about 0.1% by weight of the consumer product.

14. A method of modulating irradiance from a non-uniform light emitting source on a target tissue, comprising topically applying the light modulating cosmetic composition of any one of claims 1 to 10 or the consumer product of any one of claims 11 to 13 to the target tissue, optionally wherein the target tissue is skin, hair and / or nails.

15. A method of preparing a consumer product comprising: (a) adding the light-modulating cosmetic composition of any one of claims 1 to 10 to a cosmetic base to form a mixture; (b) stirring the mixture to achieve homogeneity; (c) optionally emulsifying the mixture; (d) optionally cooling the mixture; and (e) optionally adjusting the pH of the mixture.

Images